Sales of the company's widely used Biktarvy drug, a treatment for HIV, climbed 21% year-over-year in Q4 to $3.8 billion, compared with analysts' average estimate of roughly $3.4 billion.

Meanwhile, although patients switching to both drugs from their old regimen saw an increase in weight, it was significantly less with Dovato compared to Biktarvy, with average gains of 1.81kg and ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. "Gilead delivered another exceptionally ...

Weight gain medications—like some steroid-, cannabis-, and hormone-based prescriptions or supplements—may promote weight gain. Some chronic illnesses, surgery, and trauma to the body can lead ...

Fortune’s Term Sheet newsletter covers the latest news, insights, and analysis on private equity, venture capital, start-ups, mergers and acquisitions, high-value deals, and the dealmakers ...

National Helpline at 800-662-4357 for information on support and treatment facilities in your area. The right medicine for you depends on your symptoms, other medications you take, and how severe your ...

Companies with Quarterly Profit Growth in excess of 50% ...

After hours: February 14 at 6:30:45 PM EST Loading Chart for DRUG ...